Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

715 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D. Smolen J, et al. Among authors: mease p. Ann Rheum Dis. 2009 Jun;68(6):797-804. doi: 10.1136/ard.2008.101659. Epub 2008 Nov 17. Ann Rheum Dis. 2009. PMID: 19015207 Free PMC article. Clinical Trial.
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Moreland LW, et al. Among authors: mease pj. Ann Intern Med. 1999 Mar 16;130(6):478-86. doi: 10.7326/0003-4819-130-6-199903160-00004. Ann Intern Med. 1999. PMID: 10075615 Clinical Trial.
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Furst DE, et al. Among authors: mease pj. Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii2-ii12. doi: 10.1136/ard.2004.029272. Ann Rheum Dis. 2004. PMID: 15479866 Free PMC article. Review. No abstract available.
OMERACT 7 psoriatic arthritis workshop: synopsis.
Gladman DD, Strand V, Mease PJ, Antoni C, Nash P, Kavanaugh A. Gladman DD, et al. Among authors: mease pj. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii115-6. doi: 10.1136/ard.2004.032615. Ann Rheum Dis. 2005. PMID: 15708925 Free PMC article. Review.
Seronegative spondyloarthropathies: to lump or split?
Nash P, Mease PJ, Braun J, van der Heijde D. Nash P, et al. Among authors: mease pj. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii9-13. doi: 10.1136/ard.2004.033654. Ann Rheum Dis. 2005. PMID: 15708947 Free PMC article. Review.
Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM; iRAMT Study Group. Fleischmann RM, et al. Among authors: mease pj. Curr Med Res Opin. 2005 Aug;21(8):1181-90. doi: 10.1185/030079905X53261. Curr Med Res Opin. 2005. PMID: 16083527 Clinical Trial.
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Furst DE, et al. Among authors: mease pj. Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv2-14. doi: 10.1136/ard.2005.044941. Ann Rheum Dis. 2005. PMID: 16239380 Free PMC article. Review. No abstract available.
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors.
Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, Van Riel PL. Fransen J, et al. Among authors: mease pj. Ann Rheum Dis. 2006 Oct;65(10):1373-8. doi: 10.1136/ard.2006.051706. Epub 2006 Apr 27. Ann Rheum Dis. 2006. PMID: 16644783 Free PMC article.
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Gladman DD, et al. Among authors: mease pj. Ann Rheum Dis. 2007 Feb;66(2):163-8. doi: 10.1136/ard.2006.057901. Epub 2006 Oct 17. Ann Rheum Dis. 2007. PMID: 17046964 Free PMC article. Clinical Trial.
715 results